I really don’t know what to make of this hugely popular FTSE 100 second income stock. I don’t know if it’s a brilliant British blue-chip having a bad run, or a bad blue-chip that’s getting what it deserves.
The one thing I know for sure is that the GSK (LSE: GSK) share price hasn’t performed how I expected when I bought the pharmaceutical stock at the start of this year.
And now I’m asking myself three questions. Should I take advantage of its recent troubles to buy more?Should I sell and move on? Or hold and hope for the best?
The GSK share price is a nightmare
I have distant memories of the days when – in its former incarnation as GlaxoSmithKline – this was every income seeker’s favourite UK stock. At least, that’s how it felt at the time.
Investors bought it for its solid yield, which typically hovered around the 5% to 6% mark, and the happy expectation of share price growth on top. Then gradually, they began to worry about the drugs pipeline, that was looking a bit thin as former blockbuster treatments went off patent, and new ones were slow to arrive.
CEO Emma Walmsley, appointed in 2017, set to work putting that right but had to sacrifice dividend growth to do it. With shareholder payouts frozen at 80p per share and the stock refusing to rally as hoped, investors drifted away.
Hiving off consumer arm Haleon in 2022 didn’t bring back them back. I thought GSK looked good value in January and dived in. There were more problems just around the corner.
A decent dividend yield at a bargain price
My shares slumped over the summer when a US class action claimed that a discontinued version of its blockbuster heartburn treatment Zantac caused cancer. The shares rallied when most claims were settled in a $2.2bn payout on 9 October.
But within a month they were crashing as Donald Trump won the US presidency and appointed controversial vaccine sceptic Robert F Kennedy, Jr, as US Health Secretary. Trump is taking on big pharma.
The GSK share price is now down 24.6% in the last six bumpy months, although it’s still up 5.95% over the last year. It looks terrific value though, trading at just 8.63 times earnings. In the old days, it was routinely valued at 15 times.
Plus the previously underwhelming yield has jumped to 4.63%. So to my three questions. Should I buy more? Answer: no. There’s now a big question mark over the sector while we wait to see what Kennedy does. Gambling on buying more would be a blind bet.
Should I sell? I’m sitting on a 20% loss and I’m not too happy about crystallising that. A lot of bad news has been priced in, and maybe things won’t be as bad as they look.
Which brings me to the final question and yes, I’ll hold. Investing is a long-term game and things may get better at GSK. Although being honest, I wish I’d never bought it at all. There are better passive income stocks out there.
The post Down 25% with a 4.32% yield and P/E of 8.6! Is this my best second income stock or worst? appeared first on The Motley Fool UK.
But this isn’t the only opportunity that’s caught my attention this week. Here are:
5 Shares for the Future of Energy
Investors who don’t own energy shares need to see this now.
Because Mark Rogers — The Motley Fool UK’s Director of Investing — sees 2 key reasons why energy is set to soar.
While sanctions slam Russian supplies, nations are also racing to achieve net zero emissions, he says. Mark believes 5 companies in particular are poised for spectacular profits.
Open this new report — 5 Shares for the Future of Energy — and discover:
Britain’s Energy Fort Knox, now controlling 30% of UK energy storage
How to potentially get paid by the weather
Electric Vehicles’ secret backdoor opportunity
One dead simple stock for the new nuclear boom
Click the button below to find out how you can get your hands on the full report now, and as a thank you for your interest, we’ll send you one of the five picks — absolutely free!
Grab your FREE Energy recommendation now
More reading
After it crashed 25%, should I buy this former stock market darling in my Stocks and Shares ISA?
Is GSK a bargain now the share price is near 1,333p?
Down 28%! What’s going on with GSK’s share price?
This latest FTSE 100 dip could be an unmissable opportunity to pick up cut-price stocks
These 2 former stock market darlings are trying my patience! Time to sell?
Harvey Jones has positions in GSK. The Motley Fool UK has recommended GSK and Haleon Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.
